发布求助
文献互助 智能选刊 最新文献

Current opinion in virology最新文献

筛选
英文 中文
Virus genomics: what is being overlooked? 病毒基因组学:什么被忽视了?
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2022.101200
Kristopher Kieft , Karthik Anantharaman
{"title":"Virus genomics: what is being overlooked?","authors":"Kristopher Kieft ,&nbsp;Karthik Anantharaman","doi":"10.1016/j.coviro.2022.101200","DOIUrl":"10.1016/j.coviro.2022.101200","url":null,"abstract":"<div><p>Viruses are diverse biological entities that influence all life. Even with limited genome sizes, viruses can manipulate, drive, steal from, and kill their hosts. The field of virus genomics, using sequencing data to understand viral capabilities, has seen significant innovations in recent years. However, with advancements in metagenomic sequencing and related technologies, the bottleneck to discovering and employing the virosphere has become the analysis of genomes rather than generation. With metagenomics rapidly expanding available data, vital components of virus genomes and features are being overlooked, with the issue compounded by lagging databases and bioinformatics methods. Despite the field moving in a positive direction, there are noteworthy points to keep in mind, from how software-based virus genome predictions are interpreted to what information is overlooked by current standards. In this review, we discuss conventions and ideologies that likely need to be revised while continuing forward in the study of virus genomics.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":"53 ","pages":"Article 101200"},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201916/pdf/nihms-1770501.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9498636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Broad neutralizing antibody-based strategies to tackle influenza 以广泛中和抗体为基础的应对流感策略
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2022.101207
Xiaoyu Sun , Zhiyang Ling , Zhuo Yang, Bing Sun
{"title":"Broad neutralizing antibody-based strategies to tackle influenza","authors":"Xiaoyu Sun ,&nbsp;Zhiyang Ling ,&nbsp;Zhuo Yang,&nbsp;Bing Sun","doi":"10.1016/j.coviro.2022.101207","DOIUrl":"10.1016/j.coviro.2022.101207","url":null,"abstract":"<div><p><span><span>Influenza viruses cause occasional pandemics and annual epidemics, thus persist as a threat to human society. The high variability of viral envelope proteins resulting from </span>antigenic shift and </span>antigenic drift<span><span><span> allows influenza viruses to escape human herd immunity<span><span>. During the past decade, along with the breakthroughs of human monoclonal antibody<span><span> technologies, many broad reactive monoclonal antibodies (mAbs) that neutralize diverse influenza subtypes have been isolated and characterized. The achievements in this field have provided potential candidates of anti-influenza therapeutics and shed light on the design of universal </span>influenza vaccines. Here, we review the broad </span></span>neutralizing antibodies (bnAbs) targeting the </span></span>virus </span>surface proteins, summarize their epitopes, broad spectrum and immunological mechanisms of action and discuss the design of universal influenza vaccines inspired by bnAbs.</span></p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":"53 ","pages":"Article 101207"},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39897908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
From high-throughput to therapeutic: host-directed interventions against influenza viruses 从高通量到治疗性:针对流感病毒的宿主定向干预
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2021.12.014
Joseph D Trimarco , Nicholas S Heaton
{"title":"From high-throughput to therapeutic: host-directed interventions against influenza viruses","authors":"Joseph D Trimarco ,&nbsp;Nicholas S Heaton","doi":"10.1016/j.coviro.2021.12.014","DOIUrl":"10.1016/j.coviro.2021.12.014","url":null,"abstract":"<div><p><span>Influenza viruses are simultaneously supported and antagonized by factors within the host cell. This close relationship is the theoretical basis for future antivirals that target the host rather than the virus itself, a concept termed host-directed therapeutics. Genetic screening has led to the identification of host factors capable of modulating influenza </span>virus infections, and these factors represent candidate targets for host-directed antiviral strategies. Despite advances in understanding host targets, however, there are currently no host-directed interventions for influenza viruses in clinical use. In this brief review, we discuss some host factors identified in knockout/knockdown and overexpression screens that could potentially be targeted as host-directed influenza intervention strategies. We further comment on the feasibility of changing gene expression in the respiratory tract with RNA delivery vectors and transient CRISPR-mediated gene targeting.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":"53 ","pages":"Article 101198"},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9227514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Teaching old dogmas new tricks: recent insights into the nuclear import of HIV-1 教旧教条新把戏:最近对HIV-1核输入的见解
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2022.101203
Adarsh Dharan, Edward M Campbell
{"title":"Teaching old dogmas new tricks: recent insights into the nuclear import of HIV-1","authors":"Adarsh Dharan,&nbsp;Edward M Campbell","doi":"10.1016/j.coviro.2022.101203","DOIUrl":"10.1016/j.coviro.2022.101203","url":null,"abstract":"<div><p><span>A hallmark feature of lentiviruses<span>, which separates them from other members of the retrovirus<span><span> family, is their ability to infect non-dividing cells by traversing the nuclear pore complex. The viral determinant that mediates HIV-1 nuclear import is the </span>viral capsid (CA) protein, which forms the conical core protecting the HIV-1 genome in a mature virion. Recently, a series of novel approaches developed to monitor post-fusion events in infection have challenged previous textbook models of the </span></span></span>viral life cycle<span>, which envisage reverse transcription and disassembly of the capsid core as events that complete in the cytoplasm. In this review, we summarize these recent findings and describe their implications on our understanding of the spatiotemporal staging of HIV-1 infection with a focus on the nuclear import and its implications in other aspects of the viral lifecycle.</span></p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":"53 ","pages":"Article 101203"},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9595530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world 噬菌体库作为发展中国家快速和经济有效地管理抗菌素耐药性的潜在工具
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2022.101208
Tobi Nagel , Lillian Musila , Milkah Muthoni , Mikeljon Nikolich , Jesca L Nakavuma , Martha RJ Clokie
{"title":"Phage banks as potential tools to rapidly and cost-effectively manage antimicrobial resistance in the developing world","authors":"Tobi Nagel ,&nbsp;Lillian Musila ,&nbsp;Milkah Muthoni ,&nbsp;Mikeljon Nikolich ,&nbsp;Jesca L Nakavuma ,&nbsp;Martha RJ Clokie","doi":"10.1016/j.coviro.2022.101208","DOIUrl":"10.1016/j.coviro.2022.101208","url":null,"abstract":"<div><p>Lower and middle-income countries seldom develop vaccines and therapeutics for their own populations and are dependent on supplies from industrialized countries, which are often hampered by financial or supply chain limitations. This has resulted in major delays in delivery with significant loss of life, as seen with the coronavirus pandemic. Since the vast majority of deaths from the antimicrobial resistance crisis are expected to occur in developing countries, there is an urgent need for in-country production of antibacterial therapies such as phages. Nationally controlled phage banks might provide such a solution since locally developed phage therapies tailored to endemic bacterial strains could offer cost-effective antibiotic alternatives.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":"53 ","pages":"Article 101208"},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9155372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
An overview of the current state of phage therapy for the treatment of biofilm-related infections 噬菌体治疗生物膜相关感染的现状综述
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2022.101209
Diana P Pires , Luciana Meneses , Ana C Brandão , Joana Azeredo
{"title":"An overview of the current state of phage therapy for the treatment of biofilm-related infections","authors":"Diana P Pires ,&nbsp;Luciana Meneses ,&nbsp;Ana C Brandão ,&nbsp;Joana Azeredo","doi":"10.1016/j.coviro.2022.101209","DOIUrl":"10.1016/j.coviro.2022.101209","url":null,"abstract":"<div><p>Bacterial biofilms are involved in many chronic and difficult-to-treat infections. Phage therapy against infectious biofilms is becoming a promising strategy, as suggested by the increasing number of publications demonstrating the efficacy of phages against <em>in vitro</em> formed biofilms. However, the translation between <em>in vitro</em> results to <em>in vivo</em> phage therapy outcome is not straightforward due to the complexity of phage-biofilm interactions in clinical contexts. Here, we provide a critical overview of the <em>in vitro</em> studies of phages for biofilm control of clinical pathogens, followed by the major outcomes and lessons learned from the recently reported case studies (between 2018 and 2021) of phage therapy against biofilm-related infections.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":"53 ","pages":"Article 101209"},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1879625722000165/pdfft?md5=4f57bdc6057036abc1a6e00ba72a9b05&pid=1-s2.0-S1879625722000165-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44244846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
Advances in human monoclonal antibody therapy for HBV infection 人单克隆抗体治疗HBV感染的研究进展
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2022.101205
Maxime Beretta , Hugo Mouquet
{"title":"Advances in human monoclonal antibody therapy for HBV infection","authors":"Maxime Beretta ,&nbsp;Hugo Mouquet","doi":"10.1016/j.coviro.2022.101205","DOIUrl":"10.1016/j.coviro.2022.101205","url":null,"abstract":"<div><p><span><span><span>HBV neutralizing antibodies target the </span>viral envelope antigens (HBsAg) and confer long-term immune protection in vaccinees and infected humans who seroconvert. They recognize various HBsAg epitopes, and can be armed with Fc-dependent effector functions essential for eliminating infected cells and stimulating </span>adaptive immunity<span>. Hundreds of HBsAg-specific monoclonal antibodies (mAbs) were produced from the early 80’s, but it is only recently that </span></span><em>bona fide</em> human anti-HBV mAbs were generated from vaccinees and seroconverters. Neutralizing HBV mAbs have <em>in vivo</em><span> prophylactic and therapeutic efficacy in animal models, and the capacity to decrease antigenemia and viremia<span> in infected humans. Thus, polyfunctional, potent and broad human HBV neutralizing mAbs offer novel opportunities to develop effective interventions to prevent and treat HBV infection. Here, we summarize recent findings on the humoral immune response to HBV, and explore the potential of human HBV neutralizing mAbs as immunotherapeutics to help achieving a functional cure for HBV.</span></span></p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":"53 ","pages":"Article 101205"},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39753468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 12
RNA viruses and the cGAS-STING pathway: reframing our understanding of innate immune sensing RNA病毒和cGAS-STING通路:重塑我们对先天免疫感知的理解
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2022.101206
Laurence G Webb , Ana Fernandez-Sesma
{"title":"RNA viruses and the cGAS-STING pathway: reframing our understanding of innate immune sensing","authors":"Laurence G Webb ,&nbsp;Ana Fernandez-Sesma","doi":"10.1016/j.coviro.2022.101206","DOIUrl":"10.1016/j.coviro.2022.101206","url":null,"abstract":"<div><p>The past decade has provided critical information about the cytoplasmic innate immune sensing pathway of cyclic GMP-AMP synthase (cGAS) and stimulator of interferon genes (STING). These discoveries have broadened our understanding of the interconnectedness of the cGAS-STING pathway with autophagy, programmed cell death, Rig-I-like receptor (RLR) signaling, DNA independent interferon induction, and how this pathway responds to RNA virus infection. These advances highlight how multiple families of RNA viruses are restricted by and in turn have mechanisms to inhibit cGAS-STING dependent type-I interferon (IFN-I) induction. Here we review recent discoveries of how and why the cGAS-STING pathway responds to infection with RNA viruses, novel findings of RNA viral antagonism of the cGAS-STING innate immune sensing pathway, and attempt to provide context for a shift in thinking as to how critical this DNA sensing pathway is for the restriction of a wide range of RNA viruses.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":"53 ","pages":"Article 101206"},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S187962572200013X/pdfft?md5=4aa0662173b2f513f95bb6679a729650&pid=1-s2.0-S187962572200013X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39935116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 32
Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy 抗狂犬病单克隆抗体:目前在预防和治疗中的应用
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2022.101204
Guilherme Dias de Melo , Jan Hellert , Rajesh Gupta , Davide Corti , Hervé Bourhy
{"title":"Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy","authors":"Guilherme Dias de Melo ,&nbsp;Jan Hellert ,&nbsp;Rajesh Gupta ,&nbsp;Davide Corti ,&nbsp;Hervé Bourhy","doi":"10.1016/j.coviro.2022.101204","DOIUrl":"10.1016/j.coviro.2022.101204","url":null,"abstract":"<div><p>Rabies is a severe viral infection that causes an acute encephalomyelitis, which presents a case fatality of nearly 100% after the manifestation of neurological clinical signs. Rabies can be efficiently prevented with post-exposure prophylaxis (PEP), composed of vaccines and anti-rabies immunoglobulins (RIGs); however, no treatment exists for symptomatic rabies. The PEP protocol faces access and implementation obstacles in resource-limited settings, which could be partially overcome by substituting RIGs for monoclonal antibodies (mAbs). mAbs offer lower production costs, consistent supply availability, long-term storage/stability, and an improved safety profile. Here we summarize the key features of the different available mAbs against rabies, focusing on their application in PEP and highlighting their potential in a novel therapeutic approach.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":"53 ","pages":"Article 101204"},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1879625722000116/pdfft?md5=f129e04c5554a8994f4c77c223e81f8c&pid=1-s2.0-S1879625722000116-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39774081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Neutralizing monoclonal antibodies against highly pathogenic coronaviruses 抗高致病性冠状病毒的中和单克隆抗体
IF 5.9 2区 医学
Current opinion in virology Pub Date : 2022-04-01 DOI: 10.1016/j.coviro.2021.12.015
Rong Xiang , Yang Wang , Lili Wang , Xiaoqian Deng , Shanshan Huo , Shibo Jiang , Fei Yu
{"title":"Neutralizing monoclonal antibodies against highly pathogenic coronaviruses","authors":"Rong Xiang ,&nbsp;Yang Wang ,&nbsp;Lili Wang ,&nbsp;Xiaoqian Deng ,&nbsp;Shanshan Huo ,&nbsp;Shibo Jiang ,&nbsp;Fei Yu","doi":"10.1016/j.coviro.2021.12.015","DOIUrl":"10.1016/j.coviro.2021.12.015","url":null,"abstract":"<div><p>The pandemic of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) is a continuing worldwide threat to human health and social economy. Historically, SARS-CoV-2 follows SARS and MERS as the third coronavirus spreading across borders and continents, but far more dangerous with long-lasting symptomatic consequences. The current situation is strong evidence that coronaviruses will continue to be pathogens of consequence in the future, thus calling for the development of neutralizing antibody-based prophylactics and therapeutics for prevention and treatment of COVID-19 and other human coronavirus diseases. This review summarized the progresses of developing neutralizing monoclonal antibodies against infection of SARS-CoV-2, SARS-CoV, and MERS-CoV, and discussed their potential applications in prevention and treatment of COVID-19 and other human coronavirus diseases.</p></div>","PeriodicalId":11082,"journal":{"name":"Current opinion in virology","volume":"53 ","pages":"Article 101199"},"PeriodicalIF":5.9,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10694772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信